RU2010147881A - ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА - Google Patents
ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА Download PDFInfo
- Publication number
- RU2010147881A RU2010147881A RU2010147881/15A RU2010147881A RU2010147881A RU 2010147881 A RU2010147881 A RU 2010147881A RU 2010147881/15 A RU2010147881/15 A RU 2010147881/15A RU 2010147881 A RU2010147881 A RU 2010147881A RU 2010147881 A RU2010147881 A RU 2010147881A
- Authority
- RU
- Russia
- Prior art keywords
- active ingredient
- ethyl
- cycloheptanecarbonyloxy
- octane
- bicyclo
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract 3
- 229940127557 pharmaceutical product Drugs 0.000 title claims abstract 3
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 239000004480 active ingredient Substances 0.000 claims abstract 22
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims abstract 11
- 239000003149 muscarinic antagonist Substances 0.000 claims abstract 11
- -1 1-phenyl-cycloheptanecarbonyloxy Chemical group 0.000 claims abstract 9
- WZKCUYWQFWEJSC-AKFGGTECSA-O [(3r)-1-[2-oxo-2-(pyridin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate Chemical compound O([C@@H]1C2CC[N+](CC2)(C1)CC(=O)NC=1N=CC=CC=1)C(=O)C1(C=2C=CC=CC=2)CCCCCC1 WZKCUYWQFWEJSC-AKFGGTECSA-O 0.000 claims abstract 5
- 239000002253 acid Substances 0.000 claims abstract 5
- 150000001450 anions Chemical class 0.000 claims abstract 5
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims abstract 4
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims abstract 3
- PWJNDVAKQLOWRZ-UHFFFAOYSA-M 1-hydroxynaphthalene-2-sulfonate Chemical compound C1=CC=C2C(O)=C(S([O-])(=O)=O)C=CC2=C1 PWJNDVAKQLOWRZ-UHFFFAOYSA-M 0.000 claims abstract 2
- PWJNDVAKQLOWRZ-UHFFFAOYSA-N 1-hydroxynaphthalene-2-sulfonic acid Chemical class C1=CC=C2C(O)=C(S(O)(=O)=O)C=CC2=C1 PWJNDVAKQLOWRZ-UHFFFAOYSA-N 0.000 claims abstract 2
- LFXZSGVZSSMCMB-UHFFFAOYSA-M 2,5-dichlorobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC(Cl)=CC=C1Cl LFXZSGVZSSMCMB-UHFFFAOYSA-M 0.000 claims abstract 2
- VHTIGXNEAZTOFX-IYKJVDJMSA-O [(3r)-1-[2-[(2-methylpyridin-4-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate Chemical compound C1=NC(C)=CC(NC(=O)C[N+]23CCC(CC2)[C@H](C3)OC(=O)C2(CCCCCC2)C=2C=CC=CC=2)=C1 VHTIGXNEAZTOFX-IYKJVDJMSA-O 0.000 claims abstract 2
- DQCMINAFBHBOOI-FZCUKYEHSA-O [(3r)-1-[2-[(5-fluoropyridin-2-yl)amino]-2-oxoethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate Chemical compound N1=CC(F)=CC=C1NC(=O)C[N+]1(C[C@@H]2OC(=O)C3(CCCCCC3)C=3C=CC=CC=3)CCC2CC1 DQCMINAFBHBOOI-FZCUKYEHSA-O 0.000 claims abstract 2
- UDWRGWVYJNZRME-HBUOLCFLSA-O [(3r)-1-[2-oxo-2-(pyrazin-2-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate Chemical compound O([C@@H]1C2CC[N+](CC2)(C1)CC(=O)NC=1N=CC=NC=1)C(=O)C1(C=2C=CC=CC=2)CCCCCC1 UDWRGWVYJNZRME-HBUOLCFLSA-O 0.000 claims abstract 2
- ILQZJPKOIMGJOM-LMEDFRRQSA-O [(3r)-1-[2-oxo-2-(pyridin-3-ylamino)ethyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 1-phenylcycloheptane-1-carboxylate Chemical compound O([C@@H]1C2CC[N+](CC2)(C1)CC(=O)NC=1C=NC=CC=1)C(=O)C1(C=2C=CC=CC=2)CCCCCC1 ILQZJPKOIMGJOM-LMEDFRRQSA-O 0.000 claims abstract 2
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000003842 bromide salts Chemical class 0.000 claims abstract 2
- 229940124225 Adrenoreceptor agonist Drugs 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 4
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- GHQXRNRNBBBEQN-UHFFFAOYSA-N n-cyclohexyl-3-[2-(3-fluorophenyl)ethylamino]-n-[2-[2-(4-hydroxy-2-oxo-3h-1,3-benzothiazol-7-yl)ethylamino]ethyl]propanamide Chemical group C1=2SC(=O)NC=2C(O)=CC=C1CCNCCN(C(=O)CCNCCC=1C=C(F)C=CC=1)C1CCCCC1 GHQXRNRNBBBEQN-UHFFFAOYSA-N 0.000 claims 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Natural products CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 2
- UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 claims 1
- OSNANICDBBZIMG-IBGZPJMESA-N 7-[(1r)-2-[2-[3-[2-(2-chlorophenyl)ethylamino]propylsulfanyl]ethylamino]-1-hydroxyethyl]-4-hydroxy-3h-1,3-benzothiazol-2-one Chemical compound C([C@H](O)C=1C=2SC(=O)NC=2C(O)=CC=1)NCCSCCCNCCC1=CC=CC=C1Cl OSNANICDBBZIMG-IBGZPJMESA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical group C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 229960004078 indacaterol Drugs 0.000 claims 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- ZVULMJYRVAVKCP-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-n-[2-[2-(4-hydroxy-2-oxo-3h-1,3-benzothiazol-7-yl)ethylamino]ethyl]-3-(2-naphthalen-1-ylethoxy)propanamide Chemical compound C1=CC=C2C(CCOCCC(=O)N(CCNCCC=3C=4SC(=O)NC=4C(O)=CC=3)CCN(CC)CC)=CC=CC2=C1 ZVULMJYRVAVKCP-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 2
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 abstract 2
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0808710A GB0808710D0 (en) | 2008-05-13 | 2008-05-13 | New combination 296 |
| GB0808710.8 | 2008-05-13 | ||
| GB0900563.8 | 2009-01-14 | ||
| GB0900563A GB0900563D0 (en) | 2009-01-14 | 2009-01-14 | New combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010147881A true RU2010147881A (ru) | 2012-06-20 |
Family
ID=41318921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010147881/15A RU2010147881A (ru) | 2008-05-13 | 2009-05-12 | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110190309A1 (enExample) |
| EP (1) | EP2315589A4 (enExample) |
| JP (1) | JP2011520877A (enExample) |
| KR (1) | KR20110010725A (enExample) |
| CN (2) | CN102908624A (enExample) |
| AU (1) | AU2009247021B2 (enExample) |
| BR (1) | BRPI0912657A2 (enExample) |
| CA (1) | CA2723909A1 (enExample) |
| MX (1) | MX2010012019A (enExample) |
| RU (1) | RU2010147881A (enExample) |
| WO (1) | WO2009139708A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| JP4837800B2 (ja) | 2008-05-13 | 2011-12-14 | アストラゼネカ・アクチエボラーグ | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
| GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| KR101845257B1 (ko) | 2011-02-07 | 2018-04-04 | 삼성전자주식회사 | 이미지 센서 |
| JP2011195593A (ja) * | 2011-06-30 | 2011-10-06 | Astrazeneca Ab | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL62140C (enExample) * | 1942-12-16 | |||
| GB8334494D0 (en) * | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| GR1001529B (el) * | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| US6223485B1 (en) * | 1996-06-07 | 2001-05-01 | Herman Miller, Inc. | Wall panel system |
| KR20000029703A (ko) * | 1996-07-29 | 2000-05-25 | 존 헤덴스트룀 | 아릴시클로알칸카르복실산에스테르,그것의용도,제약학적조성물및제조방법 |
| US6613795B2 (en) * | 1996-11-11 | 2003-09-02 | Christian Noe | Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments |
| WO2002096855A2 (en) * | 2001-04-03 | 2002-12-05 | Aryx Therapeutics | Anticholinergic compounds and methods of use |
| US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
| GB0424284D0 (en) * | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| TW200738658A (en) * | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200738659A (en) * | 2005-08-29 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
| TW200825084A (en) * | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| WO2008059239A1 (en) * | 2006-11-14 | 2008-05-22 | Astrazeneca Ab | Novel compounds 514 |
| TW200833670A (en) * | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
| GB0702456D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| GB0702457D0 (en) * | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
| GB0704000D0 (en) * | 2007-03-01 | 2007-04-11 | Astrazeneca Ab | Salts 670 |
| JP4837800B2 (ja) * | 2008-05-13 | 2011-12-14 | アストラゼネカ・アクチエボラーグ | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
| JP2011195593A (ja) * | 2011-06-30 | 2011-10-06 | Astrazeneca Ab | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
-
2009
- 2009-05-12 CN CN2012104520326A patent/CN102908624A/zh active Pending
- 2009-05-12 RU RU2010147881/15A patent/RU2010147881A/ru not_active Application Discontinuation
- 2009-05-12 US US12/992,226 patent/US20110190309A1/en not_active Abandoned
- 2009-05-12 EP EP09746868.0A patent/EP2315589A4/en not_active Withdrawn
- 2009-05-12 KR KR1020107025392A patent/KR20110010725A/ko not_active Withdrawn
- 2009-05-12 CN CN200980127403XA patent/CN102088976B/zh not_active Expired - Fee Related
- 2009-05-12 WO PCT/SE2009/050525 patent/WO2009139708A1/en not_active Ceased
- 2009-05-12 CA CA2723909A patent/CA2723909A1/en not_active Abandoned
- 2009-05-12 JP JP2011509442A patent/JP2011520877A/ja active Pending
- 2009-05-12 MX MX2010012019A patent/MX2010012019A/es active IP Right Grant
- 2009-05-12 AU AU2009247021A patent/AU2009247021B2/en not_active Ceased
- 2009-05-12 BR BRPI0912657A patent/BRPI0912657A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN102088976A (zh) | 2011-06-08 |
| KR20110010725A (ko) | 2011-02-07 |
| AU2009247021B2 (en) | 2012-06-07 |
| US20110190309A1 (en) | 2011-08-04 |
| CN102908624A (zh) | 2013-02-06 |
| JP2011520877A (ja) | 2011-07-21 |
| EP2315589A1 (en) | 2011-05-04 |
| CN102088976B (zh) | 2012-12-26 |
| EP2315589A4 (en) | 2013-09-11 |
| MX2010012019A (es) | 2011-03-04 |
| BRPI0912657A2 (pt) | 2016-01-26 |
| AU2009247021A1 (en) | 2009-11-19 |
| CA2723909A1 (en) | 2009-11-19 |
| WO2009139708A1 (en) | 2009-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2404771C3 (ru) | Комбинации, содержащие антимускариновые средства и бета-адренергические агонисты | |
| RU2009133261A (ru) | Комбинация антагониста мускаринового рецептора и агониста бета-2адренорецептора | |
| US20180235931A1 (en) | Use of neurokinin-1 antagonists as antitussives | |
| RU2317817C2 (ru) | Применение (1s,2r) энантиомера милнаципрана для получения лекарственного средства | |
| RU2384333C2 (ru) | Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин | |
| JP2009541443A5 (enExample) | ||
| JP2019131578A (ja) | 医薬配合剤 | |
| JP2008500986A5 (enExample) | ||
| RU2009111388A (ru) | Органические соединения | |
| ES2356093T3 (es) | Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y paracetamol. | |
| JP2007533686A5 (enExample) | ||
| JP2008521827A5 (enExample) | ||
| WO2006125042A1 (en) | Method for the treatment of drug-induced sexual dysfunction | |
| RU2011146032A (ru) | Соединения-агонисты рецептора 5-ht4 для лечения расстройств познавательной способности | |
| RU2010147881A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА | |
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| AR076175A1 (es) | Combinaciones para el tratamiento de enfermedades respiratorias. | |
| RU2011105463A (ru) | ФАРМАЦЕВТИЧЕСКИЙ ПРОДУКТ, СОДЕРЖАЩИЙ АНТАГОНИСТ МУСКАРИНОВОГО РЕЦЕПТОРА И АГОНИСТ β2-АДРЕНОРЕЦЕПТОРА | |
| JP2005531612A (ja) | ネフォパムの製剤および痛みの治療におけるその使用 | |
| JP6116679B2 (ja) | （１ｒ，４ｒ）−６’−フルオロ−Ｎ，Ｎ−ジメチル−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンおよび抗けいれん剤を含む医薬組成物 | |
| RU2010144795A (ru) | Применение комбинации уденафила и алфузозина или оксибутинина для лечения гиперактивного мочевого пузыря | |
| RU2013149635A (ru) | Соединения солифенацина и слюнные стимулянты для лечения гиперактивности мочевого пузыря | |
| KR20160067193A (ko) | 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제 | |
| KR20100040294A (ko) | 전립선 비대에 수반되는 하부 요로 증상의 개선용 의약 조성물 | |
| RU2008108175A (ru) | Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20130726 |